-
Recorna and Starna Therapeutics Join Forces to Advance RNA Gene Editing in Lung Diseases
•
Recorna (Guangzhou) Biotechnology Co., Ltd, a pioneering RNA editing therapy startup based in China, has entered into a strategic partnership with Starna Therapeutics, an mRNA specialist based in Suzhou. This alliance aims to combine their expertise to delve into the research and application of RNA gene editing drugs for lung…
-
Jiangsu Synthgene and Starna Therapeutics Join Forces in mRNA Technology Advancement
•
China’s Jiangsu Synthgene Biotechnology Co., Ltd has announced a strategic partnership with Suzhou-based Starna Therapeutics, an RNA drug developer. The collaboration will focus on mRNA raw materials, lipid chemistry, lipid nanoparticle (LNP) technology, and complex preparations, among other areas. Financial details of the agreement have not been disclosed. Synthgene and…
